Meeting
2014 Genitourinary Cancers Symposium
Heterogeneity of intermediate prognosis patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.
Authors
Avishay Sella
Assaf Harofeh Medical Center, Zerifin, Israel
Avishay Sella , M. Dror Michaelson , Ewa M. Matczak , Ronit Simantov , Mariajose Lechuga , Xun Lin , Robert A. Figlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT00077974, NCT00083889, NCT00137423, NCT00267748, NCT00338884, NCT00054886
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 446)
DOI
10.1200/jco.2014.32.4_suppl.446
Abstract #
446
Poster Bd #
D18
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.
First Author: Rana R. McKay
Poster
2014 Genitourinary Cancers Symposium
Treatment pattern and prognosis in Japanese patients with metastatic renal cell carcinoma (mRCC) with favorable or intermediate MSKCC risk factors in the era of molecular targeted therapy.
First Author: Nobuo Shinohara
Poster
2012 Genitourinary Cancers Symposium
Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).
First Author: Bernard J. Escudier
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-word evidence in patients treated with pazopanib for advanced/metastatic renal cell carcinoma (mRCC): The APOLON study.
First Author: Antoine Thiery-Vuillemin